JP2006520777A - Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 - Google Patents

Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 Download PDF

Info

Publication number
JP2006520777A
JP2006520777A JP2006506327A JP2006506327A JP2006520777A JP 2006520777 A JP2006520777 A JP 2006520777A JP 2006506327 A JP2006506327 A JP 2006506327A JP 2006506327 A JP2006506327 A JP 2006506327A JP 2006520777 A JP2006520777 A JP 2006520777A
Authority
JP
Japan
Prior art keywords
combination
composition
inhibitory activity
diabetes
pde5 inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006506327A
Other languages
English (en)
Japanese (ja)
Inventor
ムンロ バーゲス ギリアン
マイケル ギッブス アール
ピーター ウェイマン クリストファー
Original Assignee
ファイザー・プロダクツ・インク
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファイザー・プロダクツ・インク filed Critical ファイザー・プロダクツ・インク
Publication of JP2006520777A publication Critical patent/JP2006520777A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006506327A 2003-03-17 2004-03-04 Ｐｄｅ５阻害剤を用いる１型糖尿病の治療 Pending JP2006520777A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45527703P 2003-03-17 2003-03-17
PCT/IB2004/000696 WO2004082667A1 (fr) 2003-03-17 2004-03-04 Traitement du diabete insulino-dependant a l'aide d'inhibiteurs de pde5

Publications (1)

Publication Number Publication Date
JP2006520777A true JP2006520777A (ja) 2006-09-14

Family

ID=33029981

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006506327A Pending JP2006520777A (ja) 2003-03-17 2004-03-04 Ｐｄｅ５阻害剤を用いる１型糖尿病の治療

Country Status (7)

Country Link
EP (1) EP1605925A1 (fr)
JP (1) JP2006520777A (fr)
BR (1) BRPI0408500A (fr)
CA (1) CA2519357A1 (fr)
MX (1) MXPA05009242A (fr)
TW (1) TW200503666A (fr)
WO (1) WO2004082667A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
JP2021506983A (ja) * 2017-12-19 2021-02-22 マレシル リサーチ アンド テクノロジー エルエルシー 糖尿病性足潰瘍の治療方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005235306B2 (en) * 2004-04-19 2008-08-21 Loma Linda University Composition and method of decreasing renal ischemic damage
WO2007010337A2 (fr) * 2005-07-15 2007-01-25 Proxomed Medizintechnik Gmbh Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
EP2152663B1 (fr) 2007-06-04 2014-03-19 Ben Gurion University of the Negev Research and Development Authority Composés triarylés et compositions les comprenant
SG10201709195TA (en) * 2012-11-13 2017-12-28 Nusirt Sciences Inc Compositions and methods for increasing energy metabolism
JP6154025B2 (ja) 2012-12-24 2017-06-28 ニューロガストルクス，インコーポレイテッド Ｇｉ管障害を治療するための方法
WO2015068156A1 (fr) 2013-11-05 2015-05-14 Ben-Gurion University Of The Negev Research And Development Authority Composés pour le traitement du diabète et des complications pathologiques qui en résultent
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2346937A1 (fr) * 1998-10-15 2000-04-27 Per O. G. Arkhammar Interventions therapeutiques specifiques obtenues par interference avec redistribution et ou ciblage
KR100353014B1 (ko) * 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
DE19944161A1 (de) * 1999-09-15 2001-03-22 Bayer Ag Neue Kombination zur Behandlung von sexueller Dysfunktion
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
NZ523108A (en) * 2000-06-30 2005-04-29 Pfizer Method of treating diabetic complications i.e. peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies with cGMP PDE5 inhibitors such as sildenafil
CA2419033A1 (fr) * 2000-08-11 2002-02-21 Earl Michael Gibbs Traitement du syndrome de la resistance a l'insuline
MXPA03006936A (es) * 2001-02-02 2003-11-18 Pfizer Tratamiento de diabetes mellitus.
MXPA03006310A (es) * 2001-03-16 2003-09-16 Pfizer Compuestos farmaceuticamente activos.
GB0106631D0 (en) * 2001-03-16 2001-05-09 Pfizer Ltd Pharmaceutically active compounds
US6479493B1 (en) * 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
US20030114469A1 (en) * 2001-09-27 2003-06-19 Cohen David Saul Combinations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009515816A (ja) * 2005-08-04 2009-04-16 トランスフオーム・フアーマシユーチカルズ・インコーポレーテツド フェノフィブレートおよびスタチンを含んでなる新規調合物、ならびに関連する処置方法
JP2021506983A (ja) * 2017-12-19 2021-02-22 マレシル リサーチ アンド テクノロジー エルエルシー 糖尿病性足潰瘍の治療方法

Also Published As

Publication number Publication date
EP1605925A1 (fr) 2005-12-21
MXPA05009242A (es) 2006-04-18
TW200503666A (en) 2005-02-01
BRPI0408500A (pt) 2006-03-07
WO2004082667A1 (fr) 2004-09-30
CA2519357A1 (fr) 2004-09-30

Similar Documents

Publication Publication Date Title
US20040186046A1 (en) Treatment of type 1 diabetes with PDE5 inhibitors
JP6189374B2 (ja) 糖尿病療法
JP2021095409A (ja) 心臓保護及び腎臓保護の抗糖尿病治療におけるリナグリプチンの使用
JP2018030872A (ja) 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体
EP2531187B1 (fr) Stimulateurs de sgc ou activateurs de sgc seuls ou en combinaison avec des inhibiteurs de pde5 pour le traitement de la mucoviscidose
JP2017081984A (ja) Ｄｐｐ−４阻害剤（リナグリプチン）を任意で他の抗糖尿病薬と組み合わせて含む抗糖尿病薬
US20020165237A1 (en) Treatment of the insulin resistance syndrome
JP2004506009A (ja) インスリン抵抗性症候群の治療
BRPI0620234A2 (pt) combinação farmacêutica para o tratamento de luts que compreende um inibidor da pde5 e um antagonista muscarìnico
KR20110040883A (ko) 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
JP2006520777A (ja) Ｐｄｅ５阻害剤を用いる１型糖尿病の治療
AU2006237300B2 (en) Roflumilast for the treatment of pulmonary hypertension
JP2009520806A (ja) ＰＤＥ−５阻害薬と５−α還元酵素阻害薬の医薬組合せ
KR20050004195A (ko) 신규 조합 제제
JP2005531627A (ja) 新規混合医薬
US20040132731A1 (en) Novel combination
EP1157705A2 (fr) Utilisation d'un inhibiteur de la phosphodiestérase dans la fabrication d'un médicament destiné à la stabilisation de la pression sanguine lors de l'hémodialyse
JP2003192614A (ja) 痛みを低減させるためのキット
US20040077624A1 (en) Novel combination
JP4533590B2 (ja) 脊髄損傷患者における疼痛又は痙性軽減用医薬組成物
JP2002154962A (ja) イソキノリン誘導体を含有する抗鬱、抗不安剤